Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045493 | 0.99 | GSK3B (0.62) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL13915171 | 0.89 | GSK3B (0.61) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL1673556 | 0.86 | GSK3B (0.54) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2116534 | 0.86 | GSK3B (0.61) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL1652089 | 0.85 | GSK3B (0.63) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL13915148 | 0.84 | GSK3B (0.56) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL698145 | 0.83 | GSK3B (0.71) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL2116720 | 0.83 | GSK3B (0.63) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL8344197 | 0.82 | GSK3B (0.60) | GSK3BCYP1A2CYP2D6 | |
| SCHEMBL8227082 | 0.82 | GSK3B (0.57) | GSK3BCYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4778657-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | claimed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | claimed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | claimed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | disclosed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885CYP1A2 727/4885CYP2D6 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.